Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $256,437.50 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 6,250 shares of Akero Therapeutics stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $41.03, for a total value of $256,437.50. Following the transaction, the insider now owns 169,721 shares of the company’s stock, valued at $6,963,652.63. This trade represents a 3.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Timothy Rolph also recently made the following trade(s):

• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $35.88, for a total value of $224,250.00.
• On Wednesday, March 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.53, for a total value of $556,625.00.
• On Wednesday, February 5th, Timothy Rolph sold 18,750 shares of Akero Therapeutics stock. The shares were sold at an average price of $56.51, for a total value of $1,059,562.50.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO opened at $43.04 on Wednesday. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $41.92 and a two-hundred day simple moving average of $36.76. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40. The firm has a market cap of $3.43 billion, a price-to-earnings ratio of -11.48 and a beta of -0.18.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

AKRO has been the subject of several analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Citigroup increased their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. UBS Group boosted their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. HC Wainwright increased their price target on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Finally, Canaccord Genuity Group lifted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $76.29.

Hedge Funds Weigh In On Akero Therapeutics

Several large investors have recently modified their holdings of the business. GF Fund Management CO. LTD. lifted its stake in shares of Akero Therapeutics by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company’s stock valued at $72,000 after buying an additional 321 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Akero Therapeutics by 14.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock worth $114,000 after acquiring an additional 338 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Akero Therapeutics by 19.0% in the first quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock worth $104,000 after acquiring an additional 410 shares during the period. Summit Investment Advisors Inc. grew its position in shares of Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after purchasing an additional 450 shares in the last quarter. Finally, Hsbc Holdings PLC raised its stake in shares of Akero Therapeutics by 8.5% during the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company’s stock valued at $220,000 after purchasing an additional 621 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.